Onesource Specialty Pharma Ltd
P&L
Quarterly Consolidated
vs Q2 FY25
OneSource Specialty Pharma Limited Reports Q3FY25 Revenues at INR 3,926 Million with an EBITDA of INR 1,432 Million, Demonstrating a 36.5% EBITDA Margin
29 Jan 2025 · 29 Jan 2025, 01:16 pm
Summary
OneSource Specialty Pharma Limited, a leading Indian CDMO business, announced its consolidated financial results for the quarter ended December 31, 2024. The company reported revenues of INR 3,926 million, an EBITDA of INR 1,432 million, and a normalized PAT of INR 898 million. The Q3FY25 performance highlights include a 36.5% EBITDA margin, a 18% QoQ growth in revenues, and an 85% QoQ growth in EBITDA.
Key Highlights
- 1
Revenues of INR 3,926 million grew 18% QoQ
- 2
EBITDA grew 85% QoQ to INR 1,432 million
- 3
EBITDA margin of 36.5% grew by 1,334 basis points QoQ
- 4
Q3 FY25 normalized PAT was INR 898 million, resulting in an EPS of INR 7.8 for the quarter
- 5
Strong Q3 results and impressive new business wins across various modalities
Management Comments
Mr. Neeraj Sharma
CEO, OneSource Specialty Pharma Limited
We're off to a promising start as an independent platform. Our strong Q3 results and impressive new business wins across various modalities demonstrate we're on the path to continued growth and profitability while achieving the targeted FY25 outcomes. We're committed to providing significant value and establishing ourselves as the leading Indian CDMO on a global stage.
Informational and educational content only. Not investment advice.